Desentum's operations are based on a VTT patented gene technology which can be applied to alter the structure of an allergen, i.e. a protein causing allergy, so that it will cause less allergic symptoms than the original allergen, while remaining effective in desensitisation therapy.
According to VTT, the prevalence of allergies and allergic reactions has increased in the industrialised countries, and they are now estimated to belong to the top five most costly disease groups. In Europe, the number of people suffering from allergies is estimated to exceed 80 million, while in the US the corresponding number is 65 million. It is estimated that half of the European population will suffer from an allergy by 2015.
Source: VTT Technical Research Centre of Finland